Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Venkat Pharma Ltd (532093)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532093 NSE: Pharmaceuticals & Drugs | Small Cap | Venkat Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Venkat Pharma Ltd (532093)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532093 NSE: Pharmaceuticals & Drugs | Small Cap | Venkat Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹2 Cr.
Current Price
₹0
52-Week Low / High
₹3 / 4
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
22.35%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹5 Cr.
Face Value
₹10
All Time Low / High
₹1.39 / 66.80
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'00 | Mar'01 | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.6% | 2.2% | 7.2% | 0% | 7.8% | 10.2% | -1.5% | -0.5% | -0.2% | -0.3% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 19.7 | 41.7 | 51.9 | 0 | 47.8 | 36.4 | 0 | 0 | 0 | 0 | 0 |
| Sales YoY Gr. | - | 111.5% | 24.5% | -100% | NA | -23.9% | -100% | NA | NA | NA | - |
| Adj EPS ⓘ | 0.2 | 0.1 | 0.9 | 0 | 0.4 | 0.5 | -0.5 | -0.1 | -0.1 | -0.1 | -0.1 |
| YoY Gr. | - | -50% | 1075% | -100% | NA | 14.3% | -206.3% | NA | NA | NA | - |
| BVPS (₹) ⓘ | 10.7 | 10.8 | 11.8 | 0 | 14.6 | 15.1 | -4.8 | -4.9 | -5 | -5.1 | -5.2 |
| Adj Net Profit ⓘ | 0.1 | 0 | 0.3 | 0 | 0.2 | 0.2 | -0.3 | -0.1 | -0 | -0 | -0 |
| Cash Flow from Ops. ⓘ | 0.9 | -0.8 | 0.3 | 0 | -1.5 | 0.3 | -0 | -0 | -0 | -0 | - |
| Debt/CF from Ops. ⓘ | 2.7 | -2.7 | 6.5 | 0 | -4.7 | 43.9 | -6228.5 | -12457 | -1536.2 | -14785.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -100% | -100% | NA | NA | ||||
| Adj EPS ⓘ | -193.8% | -173.5% | NA | NA | ||||
| BVPSⓘ | -192.1% | -181% | NA | NA | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'00 | Mar'01 | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1.4 | 0.7 | 8 | 0 | 3.5 | 3.2 | -11.2 | 2.7 | 1.5 | 1.8 | 1 |
| Op. Profit Mgn % ⓘ | 2.7 | 0.7 | 1.2 | 0 | 2 | 5.3 | 0 | 0 | 0 | 0 | NAN |
| Net Profit Mgn % ⓘ | 0.3 | 0.1 | 0.6 | 0 | 0.4 | 0.6 | 0 | 0 | 0 | 0 | -INF |
| Debt to Equity ⓘ | 0.7 | 0.6 | 0.5 | 0 | 1.1 | 1.8 | -6.8 | -6.6 | -7.7 | -7.6 | 3.8 |
| Working Cap Days ⓘ | 0 | 251 | 206 | 0 | 189 | 240 | 0 | 0 | 0 | 0 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 46 | 46 | 0 | 80 | 162 | 0 | 0 | 0 | 0 | 0 |
Valuation of Venkat Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Venkat Pharma Ltd FAQs
The current trading price of Venkat Pharma on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Venkat Pharma stood at ₹1.70 Cr
The latest P/E ratio of Venkat Pharma as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Venkat Pharma as of 31-Dec-1969 is -0.66.
The 52-week high of Venkat Pharma is ₹3.72 and the 52-week low is ₹3.40.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venkat Pharma is ₹0.00 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Venkat Pharma Ltd
Venkat Pharma Ltd is a public limited company registered under the Indian Companies Act 1956 and their stock is listed in Bombay Stock Exchange (BSE) and is being actively traded. Established in 1989 it started manufacturing & sales of pharma products in 1992. The company is solely into the manufacturing and export of pharmaceutical products since their inception with an unswerving dedication.
At Venkat Pharma they meticulously manufacture pharma products, and constantly improvise existing product mix, thereby carving out a niche for themselves, in the global playing field of pharma.
Their philosophy is to provide value priced and quality pharmaceutical products to the humankind at large. At Venkat, they believe, that there is no compromise on the health of a human being. Their growth rate is quite above the industry CAGR growth rates as they are growing at a rate of 35% year on year.
Product range of the company includes:
- API
- PFIs
- Finished Dosage
- Under Development
- Nutraceuticals
Milestones:
- Floated as a Pvt. Ltd Company in 1989
- Entered International Market in 1994
- Became Public Ltd company in 1995
- Issued an IPO in 1996
- Listing in Bombay Stock Exchange in 1997
- International market expansion via Product Registration Year 2000
- Started APIs manufacturing in 2001
- Strengthening of bottom line by trimming down less profitable products & markets in 2002
- Expansions initiated in Regulated Markets
Achievements/ recognition :
- It is an ISO 9001: 2000 certified organisation
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
